Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Colibiogen
- Development stage
- Unknown
- Lead developer
- Laves-Arzneimittel
- Modality
- Small Molecules, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Peptides, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Colibiogen is a naturopathic pharmaceutical product developed by Laves-Arzneimittel GmbH, primarily used for the treatment of intestinal disorders and the support of the immune system. It consists of a cell-free fermentation filtrate derived from the *Escherichia coli* strain Laves 1931 (L1931). This filtrate contains metabolic products such as glycolipids, peptides, fatty acids, and amino acids, along with biotin. It is marketed as a food for special medical purposes (FSMP) for the dietary management of irritable bowel syndrome (IBS) and is also used for inflammatory bowel diseases like Crohn's disease and colitis, as well as for post-antibiotic or post-chemotherapy rehabilitation. The product exerts anti-inflammatory and immunoregulatory effects on the intestinal mucosa, helping to restore the balance of the gut-associated lymphoid tissue (GALT).
- Brand names
- ColibiogenColibiogen oralColibiogen KinderColibiogen Laves
- Other names
- Escherichia coli strain Laves 1931 lysateE. coli L1931 fermentation filtrate
Beyond the preview
Go deeper on Colibiogen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Colibiogen.